Holen Sie sich die Stockscreener-App
9.46
3.96%
0.36
Handel nachbörslich:
9.46
Schlusskurs vom Vortag:
$9.10
Offen:
$9.19
24-Stunden-Volumen:
3.09M
Relative Volume:
1.59
Marktkapitalisierung:
$1.42B
Einnahmen:
$61.10M
Nettoeinkommen (Verlust:
$-138.36M
KGV:
-7.0074
EPS:
-1.35
Netto-Cashflow:
$-90.59M
1W Leistung:
+2.94%
1M Leistung:
+16.65%
6M Leistung:
+8.24%
1J Leistung:
+41.62%
1-Tages-Spanne:
$9.04
$9.60
1-Wochen-Bereich:
$8.98
$10.00
52-Wochen-Spanne:
$5.80
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Vergleichen Sie OCUL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
9.46 | 1.42B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-11 | Eingeleitet | Needham | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-20 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-02-09 | Eingeleitet | BofA Securities | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Ocular Therapeutix to present at Clinical Trials at the Summit 2025 - Ophthalmology Times
Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years - Yahoo Finance
Ocular's Make-Or-Break Moment: Axpaxli Data Looms For Wet AMD Market (Upgrade) (OCUL) - Seeking Alpha
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 | OCUL Stock News - GuruFocus
Ocular Therapeutix, Inc. to Present Clinical Trial Results and Insights at Summit 2025 in Las Vegas - Nasdaq
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 - GlobeNewswire
Breakthrough Eye Disease Treatment Data: Ocular Therapeutix Reveals Clinical Trial Results at CTS 2025 - Stock Titan
Ocular Therapeutix Approves Key Amendments at Annual Meeting - TipRanks
Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology - insights.citeline.com
Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) 26% Jump Shows Its Popularity With Investors - simplywall.st
Trading (OCUL) With Integrated Risk Controls - news.stocktradersdaily.com
Ameriprise Financial Inc. Purchases 40,700 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Two Sigma Investments LP Buys 45,518 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Nuveen Asset Management LLC Has $3.54 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
What is HC Wainwright’s Forecast for OCUL Q1 Earnings? - Defense World
Ocular gains as Wet AMD trial for lead asset reaches enrollment target - MSN
Ocular Therapeutix (NASDAQ:OCUL) Given Buy Rating at HC Wainwright - Defense World
Ocular Therapeutix (OCUL) Maintains "Buy" Rating with $15 Price Target | OCUL Stock News - GuruFocus
Millennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DE - Defense World
Demystifying Ocular Therapeutix: Insights From 7 Analyst Reviews - Benzinga
Ocular Therapeutix (OCUL) Advances with Axpaxli Trial Completion - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Has Debt But No Earnings; Should You Worry? - simplywall.st
Sector Update: Health Care - marketscreener.com
Ocular Shares Rise After Eye Disease Trial Nears Enrollment Completion - marketscreener.com
Ocular stock gains after wet AMD trial update (OCUL:NASDAQ) - Seeking Alpha
Ocular Therapeutix chief scientific officer sells $21,712 in stock - Investing.com Australia
Ocular Therapeutix (OCUL) Concludes Enrollment for Key Retinal T - GuruFocus
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its - GuruFocus
Ocular Therapeutix™ To Close Enrollment This Week for - GlobeNewswire
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration | OCUL Stock News - GuruFocus
Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration - Yahoo Finance
Ocular Therapeutix chief scientific officer sells $21,712 in stock By Investing.com - Investing.com Canada
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $755,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
D. E. Shaw & Co. Inc. Takes $268,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix Executives Sell Shares to Cover Tax Obligations - TradingView
Ocular Therapeutix at Stifel 2025 Forum: Eyeing a Disruptive Future By Investing.com - Investing.com Canada
(OCUL) Trading Report - news.stocktradersdaily.com
BNP Paribas Financial Markets Acquires 39,599 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Ocular Therapeutix at BioConnect: Strategic Advances in Wet AMD Treatment By Investing.com - Investing.com Canada
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Holdings Boosted by Northern Trust Corp - Defense World
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences - GlobeNewswire
Ocular Therapeutix CEO to Present at RBC, Mizuho, and Top Healthcare Conferences: Key Dates for Investors - Stock Titan
The Manufacturers Life Insurance Company Sells 2,399 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Transcript : Ocular Therapeutix, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 09 - marketscreener.com
Hsbc Holdings PLC Buys 5,853 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Tower Research Capital LLC TRC Has $76,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for OCUL - Defense World
William Blair Brokers Decrease Earnings Estimates for OCUL - Defense World
Analysts Offer Predictions for OCUL FY2026 Earnings - Defense World
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):